From the *Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; †Department of Surgery, Karolinska Institute, Stockholm, Sweden; ‡Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology, Barcelona, Spain; §Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; ∥Departments of Medicine and Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN; ¶Department of Epidemiology, Mayo Graduate School of Medicine, Rochester, MN; and #Departments of Medicine, Cell Biology and Physiology, and Human Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Pancreas. 2013 Nov;42(8):1227-37. doi: 10.1097/MPA.0b013e3182a9ad9d.
A workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI) on "Pancreatitis-Diabetes-Pancreatic Cancer" focused on the risk factors of chronic pancreatitis (CP) and diabetes mellitus (DM) on the development of pancreatic ductal adenocarcinoma (PDAC). Sessions were held on (a) an overview of the problem of PDAC; (b) CP as a risk factor of PDAC; (c) DM as a risk factor of PDAC; (d) pancreatogenic, or type 3c, DM; (e) genomic associations of CP, DM, and PDAC; (f) surveillance of high-risk populations and early detection of PDAC; and (g) effects of DM treatment on PDAC. Recent data and current understandings of the mechanisms of CP- and DM-associated factors on PDAC development were discussed, and a detailed review of the possible risks of DM treatment on the development of PDAC was provided by representatives from academia, industry, and the Food and Drug Administration. The current status of possible biomarkers of PDAC and surveillance strategies for high-risk populations were discussed, and the gaps in knowledge and opportunities for further research were elucidated. A broad spectrum of expertise of the speakers and the discussants provided an unusually productive workshop, the highlights of which are summarized in the accompanying article.
一个由美国国家糖尿病、消化和肾脏疾病研究所(NIDDK)和美国国家癌症研究所(NCI)赞助的关于“胰腺炎-糖尿病-胰腺导管腺癌”的研讨会,重点关注慢性胰腺炎(CP)和糖尿病(DM)这两个危险因素在胰腺导管腺癌(PDAC)发展过程中的作用。会议内容涵盖了以下几个方面:(a)PDAC 的问题概述;(b)CP 作为 PDAC 的一个危险因素;(c)DM 作为 PDAC 的一个危险因素;(d)胰源性或 3c 型 DM;(e)CP、DM 和 PDAC 的基因组关联;(f)高危人群的监测和 PDAC 的早期检测;以及(g)DM 治疗对 PDAC 的影响。会上讨论了最近关于 CP 和 DM 相关因素与 PDAC 发展之间机制的相关数据和现有认识,并由来自学术界、工业界和美国食品和药物管理局的代表就 DM 治疗对 PDAC 发展的可能风险进行了详细的综述。还讨论了 PDAC 的可能生物标志物的现状和高危人群的监测策略,阐明了知识空白和进一步研究的机会。演讲者和讨论者广泛的专业知识为这次研讨会提供了非常丰富的内容,研讨会的重点内容在随附的文章中进行了总结。